Evidence map›Paper›PMID 17041807›Full record

ReviewWiener medizinische Wochenschrift (1946)2006

Topical drug therapy in glaucoma.

Hemma Resch, Gerhard Garhofer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Wiener medizinische Wochenschrift (1946), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hemma ReschDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Gerhard Garhofer
Medical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucoma is defined as a progressive optic neuropathy involving characteristic structural changes in the optic nerve head and corresponding visual field defects. Elevated intraocular pressure (IOP) is a major risk and causative factor for glaucomatous optic neuropathy. Although mechanisms other than elevated IOP may contribute to the underlying pathophysiology of glaucoma, reducing IOP remains the primary goal of therapy. Recent clinical studies have shown that decreasing the IOP can delay, or in some cases prevent progression of this chronic ocular disease. Over the past decade, several new medical therapies have become available for the treatment of glaucoma. In this article a review of topical glaucoma therapy is presented.

Indexed as

Administration, TopicalAdrenergic AgonistsAntihypertensive AgentsCarbonic Anhydrase InhibitorsCholinergic AgonistsDrug CombinationsGlaucomaHumansIntraocular PressureProstaglandinsAdrenergic AgonistsAntihypertensive AgentsCarbonic Anhydrase InhibitorsCholinergic AgonistsDrug CombinationsProstaglandins

Identifiers

PMID17041807
OpenAlexW2208392406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.